Catalyst Brief

← Calendar

Readoutin 14d

Serum Institute of India Pvt. Ltd. — Cervavac as three dose regimen

Phase 3 primary completion: Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years.

Date
Dec 2026
Type
Readout
Indication
Human Papillomavirus Infection

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.